COST EFFECTIVE APPROACH IN FLOWCYTOMETRY BASED IMMUNOPHENOTYPE OF ACUTE LYMPHOBLASTIC LEUKEMIA. A TERTIARY CENTRE EXPERIENCE FROM AIIMS, NEW DELHI, INDIA
(Abstract release date: 05/21/15)
EHA Library. Tanwar P. 06/12/15; 102785; PB1612
Disclosure(s): ALL INDIA INSTITUTE OF MEDICAL SCIENCESLABORATORY ONCOLOGY UNIT, Dr B.R.A.INSTITUTE ROTARY CANCER HOSPITAL
Pranay Tanwar
Contributions
Contributions
Abstract
Abstract: PB1612
Type: Publication Only
Background
The diagnosis of acute lymphoblastic leukemia is based on morphology, cytochemistory, cytogenetics and immunophenotyping. In an under resource setting and sparsely insurance covered nation like India, the cost of investigation and treatment is one of the major barrier between disease and its curative management. With primary objective of establishing, the cost effective diagnostic panels without compromising the quality, we used primary screening antibodies panel comprising of major pan-lineage markers. This was followed by extensive secondary antibodies panel comprising of more lineage specific markers to reach a final diagnosis. In this study, we evaluated, the cost effective role of five-color primary screening antibodies to reach to the final conclusive diagnosis without compromising the quality of analysis.
Aims
Evaluation of the cost effective role of five-color primary screening antibodies panel in flowcytometry based immunophenotyping of Acute Lymphoblastic Leukemia.
Methods
A total of 234 newly diagnosed cases of Acute Leukemia from Jan 2013 to Jan 2015 were included in this study. All these cases were stratified to their respective lineages with the panel of primary screening antibodies comprising of cytoplasmic myeloperoxidase (MPO), cytoplasmic 79a (c79a), CD34, cytoplasmic CD3 (c3) and CD45.Once the lineage has been screened, then extensive secondary panel of antibodies with more specific marker of B-cell, T- cell and myeloid lineage were used to conclude for final diagnosis
Results
Of all the cases (234) evaluated 206(88%) were successfully identified on primary screening panel only, 28/234(17%) cases failed to show any specific lineage in primary screening panel. These 28 cases included 23/187(12%) B-ALL and 5/47(10%) cases of T-ALL
Summary
The five-color primary screening antibodies panel was very cost effective in identifying correct lineages in majority i.e. 88% of all cases. The absence of lineage specific marker was the most common reason for failure of the predictive power of the primary panel
Keyword(s): Acute lymphoblastic leukemia, Flow cytometry, Immunophenotype
Type: Publication Only
Background
The diagnosis of acute lymphoblastic leukemia is based on morphology, cytochemistory, cytogenetics and immunophenotyping. In an under resource setting and sparsely insurance covered nation like India, the cost of investigation and treatment is one of the major barrier between disease and its curative management. With primary objective of establishing, the cost effective diagnostic panels without compromising the quality, we used primary screening antibodies panel comprising of major pan-lineage markers. This was followed by extensive secondary antibodies panel comprising of more lineage specific markers to reach a final diagnosis. In this study, we evaluated, the cost effective role of five-color primary screening antibodies to reach to the final conclusive diagnosis without compromising the quality of analysis.
Aims
Evaluation of the cost effective role of five-color primary screening antibodies panel in flowcytometry based immunophenotyping of Acute Lymphoblastic Leukemia.
Methods
A total of 234 newly diagnosed cases of Acute Leukemia from Jan 2013 to Jan 2015 were included in this study. All these cases were stratified to their respective lineages with the panel of primary screening antibodies comprising of cytoplasmic myeloperoxidase (MPO), cytoplasmic 79a (c79a), CD34, cytoplasmic CD3 (c3) and CD45.Once the lineage has been screened, then extensive secondary panel of antibodies with more specific marker of B-cell, T- cell and myeloid lineage were used to conclude for final diagnosis
Results
Of all the cases (234) evaluated 206(88%) were successfully identified on primary screening panel only, 28/234(17%) cases failed to show any specific lineage in primary screening panel. These 28 cases included 23/187(12%) B-ALL and 5/47(10%) cases of T-ALL
Summary
The five-color primary screening antibodies panel was very cost effective in identifying correct lineages in majority i.e. 88% of all cases. The absence of lineage specific marker was the most common reason for failure of the predictive power of the primary panel
Keyword(s): Acute lymphoblastic leukemia, Flow cytometry, Immunophenotype
Abstract: PB1612
Type: Publication Only
Background
The diagnosis of acute lymphoblastic leukemia is based on morphology, cytochemistory, cytogenetics and immunophenotyping. In an under resource setting and sparsely insurance covered nation like India, the cost of investigation and treatment is one of the major barrier between disease and its curative management. With primary objective of establishing, the cost effective diagnostic panels without compromising the quality, we used primary screening antibodies panel comprising of major pan-lineage markers. This was followed by extensive secondary antibodies panel comprising of more lineage specific markers to reach a final diagnosis. In this study, we evaluated, the cost effective role of five-color primary screening antibodies to reach to the final conclusive diagnosis without compromising the quality of analysis.
Aims
Evaluation of the cost effective role of five-color primary screening antibodies panel in flowcytometry based immunophenotyping of Acute Lymphoblastic Leukemia.
Methods
A total of 234 newly diagnosed cases of Acute Leukemia from Jan 2013 to Jan 2015 were included in this study. All these cases were stratified to their respective lineages with the panel of primary screening antibodies comprising of cytoplasmic myeloperoxidase (MPO), cytoplasmic 79a (c79a), CD34, cytoplasmic CD3 (c3) and CD45.Once the lineage has been screened, then extensive secondary panel of antibodies with more specific marker of B-cell, T- cell and myeloid lineage were used to conclude for final diagnosis
Results
Of all the cases (234) evaluated 206(88%) were successfully identified on primary screening panel only, 28/234(17%) cases failed to show any specific lineage in primary screening panel. These 28 cases included 23/187(12%) B-ALL and 5/47(10%) cases of T-ALL
Summary
The five-color primary screening antibodies panel was very cost effective in identifying correct lineages in majority i.e. 88% of all cases. The absence of lineage specific marker was the most common reason for failure of the predictive power of the primary panel
Keyword(s): Acute lymphoblastic leukemia, Flow cytometry, Immunophenotype
Type: Publication Only
Background
The diagnosis of acute lymphoblastic leukemia is based on morphology, cytochemistory, cytogenetics and immunophenotyping. In an under resource setting and sparsely insurance covered nation like India, the cost of investigation and treatment is one of the major barrier between disease and its curative management. With primary objective of establishing, the cost effective diagnostic panels without compromising the quality, we used primary screening antibodies panel comprising of major pan-lineage markers. This was followed by extensive secondary antibodies panel comprising of more lineage specific markers to reach a final diagnosis. In this study, we evaluated, the cost effective role of five-color primary screening antibodies to reach to the final conclusive diagnosis without compromising the quality of analysis.
Aims
Evaluation of the cost effective role of five-color primary screening antibodies panel in flowcytometry based immunophenotyping of Acute Lymphoblastic Leukemia.
Methods
A total of 234 newly diagnosed cases of Acute Leukemia from Jan 2013 to Jan 2015 were included in this study. All these cases were stratified to their respective lineages with the panel of primary screening antibodies comprising of cytoplasmic myeloperoxidase (MPO), cytoplasmic 79a (c79a), CD34, cytoplasmic CD3 (c3) and CD45.Once the lineage has been screened, then extensive secondary panel of antibodies with more specific marker of B-cell, T- cell and myeloid lineage were used to conclude for final diagnosis
Results
Of all the cases (234) evaluated 206(88%) were successfully identified on primary screening panel only, 28/234(17%) cases failed to show any specific lineage in primary screening panel. These 28 cases included 23/187(12%) B-ALL and 5/47(10%) cases of T-ALL
Summary
The five-color primary screening antibodies panel was very cost effective in identifying correct lineages in majority i.e. 88% of all cases. The absence of lineage specific marker was the most common reason for failure of the predictive power of the primary panel
Keyword(s): Acute lymphoblastic leukemia, Flow cytometry, Immunophenotype
{{ help_message }}
{{filter}}